349 related articles for article (PubMed ID: 30965283)
21. Development and validation of a ferroptosis-related prognostic model for the prediction of progression-free survival and immune microenvironment in patients with papillary thyroid carcinoma.
Huang Y; Xie Z; Li X; Chen W; He Y; Wu S; Li X; Hou B; Sun J; Wang S; He Y; Jiang H; Lun Y; Zhang J
Int Immunopharmacol; 2021 Dec; 101(Pt A):108156. PubMed ID: 34624650
[TBL] [Abstract][Full Text] [Related]
22. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
Zhang J; Yang Y; Zhao J; Shi L; Xu Y; Yu K; Guo C
Pathol Res Pract; 2019 Apr; 215(4):761-765. PubMed ID: 30819583
[TBL] [Abstract][Full Text] [Related]
23. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.
Guerra A; Fugazzola L; Marotta V; Cirillo M; Rossi S; Cirello V; Forno I; Moccia T; Budillon A; Vitale M
J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706
[TBL] [Abstract][Full Text] [Related]
24. Immune Escape Mechanism is Impaired in the Microenvironment of Thyroid Lymph Node Metastasis.
Cunha LL; Nonogaki S; Soares FA; Vassallo J; Ward LS
Endocr Pathol; 2017 Dec; 28(4):369-372. PubMed ID: 28730569
[TBL] [Abstract][Full Text] [Related]
25. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
26. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
27. Novel somatic alterations underlie Chinese papillary thyroid carcinoma.
Yang C; Xu W; Gong J; Liu Z; Cui D
Cancer Biomark; 2020; 27(4):445-460. PubMed ID: 32065787
[TBL] [Abstract][Full Text] [Related]
28. Identification of biomarkers associated with cervical lymph node metastasis in papillary thyroid carcinoma: Evidence from an integrated bioinformatic analysis.
Zhang Z; Zhao S; Wang K; Shang M; Chen Z; Yang H; Chen Y; Chen B
Clin Hemorheol Microcirc; 2021; 78(2):117-126. PubMed ID: 33554894
[TBL] [Abstract][Full Text] [Related]
29. Markers of immune activation: novel biomarkers to predict the early-warning indicator of patients with papillary thyroid carcinoma.
Lu H; Zhang L; Dai Y; Ruan Y; Cao X; Cai X; Ruan S; Chen Q
Diagn Pathol; 2020 Feb; 15(1):16. PubMed ID: 32050977
[TBL] [Abstract][Full Text] [Related]
30. Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer.
Nunes LM; Ayres FM; Francescantonio IC; Saddi VA; Avelino MA; Alencar Rde C; Silva RC; Meneghini AJ; Wastowski IJ
Hum Immunol; 2013 Apr; 74(4):447-51. PubMed ID: 23261411
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
32. Genome-wide scanning for CHD1L gene in papillary thyroid carcinoma complicated with type 2 diabetes mellitus.
Kang YY; Li JJ; Sun JX; Wei JX; Ding C; Shi CL; Wu G; Li K; Ma YF; Sun Y; Qiao H
Clin Transl Oncol; 2021 Dec; 23(12):2536-2547. PubMed ID: 34245428
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.
Siraj AK; Pratheeshkumar P; Parvathareddy SK; Bu R; Masoodi T; Iqbal K; Al-Rasheed M; Al-Dayel F; Al-Sobhi SS; Alzahrani AS; Al-Dawish M; Al-Kuraya KS
Eur J Cancer; 2019 Aug; 117():133-144. PubMed ID: 31280122
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients.
Wang W; Su X; He K; Wang Y; Wang H; Wang H; Zhao Y; Zhao W; Zarnegar R; Fahey TJ; Teng X; Teng L
Cancer; 2016 Jan; 122(2):198-206. PubMed ID: 26506214
[TBL] [Abstract][Full Text] [Related]
35. Predictive Factors of Central-Compartment Lymph Node Metastasis for Clinical N0 Papillary Thyroid Carcinoma With Strap Muscle Invasion.
Xue S; Zhang L; Pang R; Wang P; Jin M; Guo L; Zhou Y; Dong B; Chen G
Front Endocrinol (Lausanne); 2020; 11():511. PubMed ID: 33013682
[No Abstract] [Full Text] [Related]
36. Long non-coding RNA H19 may be a marker for prediction of prognosis in the follow-up of patients with papillary thyroid cancer.
Jiao X; Lu J; Huang Y; Zhang J; Zhang H; Zhang K
Cancer Biomark; 2019; 26(2):203-207. PubMed ID: 31403942
[TBL] [Abstract][Full Text] [Related]
37. The Flip Side of NIFTP: an Increase in Rates of Unfavorable Histologic Parameters in the Remainder of Papillary Thyroid Carcinomas.
Wong KS; Strickland KC; Angell TE; Nehs MA; Alexander EK; Cibas ES; Krane JF; Howitt BE; Barletta JA
Endocr Pathol; 2017 Jun; 28(2):171-176. PubMed ID: 28271380
[TBL] [Abstract][Full Text] [Related]
38. Integrated analysis of tumor microenvironment features to establish a diagnostic model for papillary thyroid cancer using bulk and single-cell RNA sequencing technology.
Wang Y; Song W; Li Y; Liu Z; Zhao K; Jia L; Wang X; Jiang R; Tian Y; He X
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16837-16850. PubMed ID: 37733241
[TBL] [Abstract][Full Text] [Related]
39. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
[TBL] [Abstract][Full Text] [Related]
40. Epitope-Specific Antitumor Immunity Suppresses Tumor Spread in Papillary Thyroid Cancer.
Ehlers M; Kuebart A; Hautzel H; Enczmann J; Reis AC; Haase M; Allelein S; Dringenberg T; Schmid C; Schott M
J Clin Endocrinol Metab; 2017 Jul; 102(7):2154-2161. PubMed ID: 27860539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
